Related Experiment Video
Updated: Feb 5, 2026
09:12
Characterization of Human Monocyte Subsets by Whole Blood Flow Cytometry Analysis
Published on: October 17, 2018
58.9K
Circulating monocyte subsets and heart failure prognosis
Elena Elchinova1,2,3, Iris Teubel4, Santiago Roura5,6
1Heart Failure Unit and Cardiology Service, Germans Trias i Pujol University Hospital, Badalona, Spain.
Plos One
|September 22, 2018
Summary
The absolute count of intermediate monocytes, not their percentage, predicts worse outcomes in heart failure (HF) patients. Higher intermediate monocyte cell counts indicate increased risk for death and composite endpoints in ambulatory HF.
Area of Science:
- Immunology
- Cardiology
- Clinical Research
Background:
- Monocytes are crucial immune cells involved in tissue repair.
- Heart failure (HF) prognosis can be influenced by immune cell dynamics.
- Understanding monocyte subset roles is vital for HF patient management.
Purpose of the Study:
- To investigate the prognostic significance of monocyte subsets in ambulatory heart failure patients.
- To determine whether monocyte percentage or absolute count is a better predictor of adverse outcomes in HF.
- To identify specific monocyte subsets associated with mortality and hospitalization in HF.
Main Methods:
- Classification of monocyte subsets: classical (CD14++/CD16-), intermediate (CD14++/CD16+), and non-classical (CD14+/CD16++).
- Assessment of percentage distribution and absolute cell counts for each subset.
- Multivariable Cox regression analyses to evaluate associations with all-cause death, HF hospitalization, and composite endpoints in 400 HF patients.
Main Results:
- Monocyte subsets as percentages were not independently associated with any endpoints.
- Absolute cell count of the intermediate monocyte subset showed independent association with increased all-cause death (HR 1.25) and composite endpoints (HR 1.20).
- Follow-up of 2.6 years revealed significant differences in outcomes based on intermediate monocyte counts.
Conclusions:
- Absolute monocyte counts, specifically for the intermediate subset, are superior to percentages for prognostic stratification in ambulatory HF patients.
- The intermediate monocyte subset serves as a valuable biomarker for increased risk of mortality and composite events in HF.
- This finding aids in refining risk assessment and potentially guiding therapeutic strategies for HF management.
More Related Videos
Related Concept Videos
01:29Heart Failure II: Pathophysiology
948
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
948
01:17Pathophysiology of Heart Failure
3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
01:27Heart Failure I: Introduction
903
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
01:22Heart Failure VI: Adjunct Therapies
348
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
01:22Heart Failure Drugs: Diuretics
981
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
981
01:30Heart Failure V: Medical Management
329
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
329